The Food and Drugs Authority (FDA), has said it is false, a publication on social media that, certain anti-malarial drugs that have been removed from the European Union (EU) market, have been proven to be dangerous and are cause of kidney failure.
A statement by the FDA, said that the false list on social media, should be disregarded, because malaria is rare in Europe and so it is impossible for the European Medicine Agency (EMA) to have registered these products for the EU.
The statement issued yesterday by acting Chief Executive Officer (CEO). Delese A. A. Darko, said that “It is worth noting that antimalarial single active ingredient formulations (monotherapies) are not used in Ghana for the treatment of malaria, exceptoral quinine tablets and suspensions for complicated malaria and Artesunate suppositories.
According to the regulator, the change of policy to combination therapy was not due to kidney failures as stated in the post but rather due to resistance leading to poor treatment outcomes.
It said that FDA as the National Pharmacovigilance Centre (a member of the WHO Programme for International Drug Monitoring since 2001), has a very robust system in place that monitors the safety of products that are used in the country and works closely with the National Malaria Control Programme, Health facilities and Communities Pharmacies.
“Kidney disease is not an adverse effect linked with any of the medicines mentioned in the post and spontaneous monitoring has not picked kidney disease as a safety concern.
The FDA, periodically samples and performs analysis of anti-malarial in its ISO accredited laboratory to ensure they are of the right quality.
The general public is, therefore advised to disregard the information and continue to use the artemisinin combination therapy as being administered under the National Malaria Control Programme”, she said.
Mrs Darko, also assured the general public of FDA’s continuous resolve to protect public health and safety at all times through collaboration with National and International Agencies.
The FDA, further encouraged the general public to provide information on any activities that are likely to endanger public health and safety with respect to FDA’s mandate through any of the following numbers; TOLL FREE NUMBER 0800151000 (free only on Airtel and Vodafone), HOTLINES (0299802932/0299802933),and SMS SHORT CODE4015 (all networks except Glo).
The public was also advised to may also reach the FDA through these additional numbers 0244337235, 0244571563 and 0208204968.